Perjeta is the 1st FDA-approved drug for the neoadjuvant treatment of breast cancer. Perjeta’s new indication is intended for patients with HER2-positive, locally advanced, inflammatory or early stage breast cancer (tumor greater than 2 cm in diameter or with positive lymph nodes) who are at ...